1.1. Introduction {#s0005}
=================

D~2~ and D~3~ receptors are expressed in high abundance in the striatum and ventral midbrain, and in lower levels in certain limbic and cortical regions ([@bb0195]). Dopamine agonists that preferentially target these D~2/3~ receptors improve motor symptoms in Parkinson\'s disease (PD) ([@bb0385]), and have been suggested to also reduce certain non-motor symptoms, such as depression ([@bb0020]). Early in the course of PD, striatal D~2/3~ binding potential (BP~ND~) increases ([@bb0350]; [@bb0355]), potentially due to reduced receptor occupancy by endogenous dopamine, or post-synaptic sensitization induced increases in receptor expression ([@bb0265]). This upregulation of D~2/3~ receptors is more extensive in the putamen than the caudate nucleus, consistent with the earlier and more prominent dopaminergic denervation of the putamen in PD ([@bb0165]). With longer disease duration, D~2/3~ expression diminishes throughout the striatum ([@bb0010]). Less attention has been devoted to the effects of PD on extrastriatal D~2/3~ expression. Some studies have reported a decrease in D~2/3~ BP~ND~ later in the course of PD, including in the medial thalamus as well as anterior cingulate, inferior temporal, and ventromedial/dorsolateral prefrontal cortices ([@bb0235]; [@bb0230]; [@bb0270]).

Due to intrinsic differences in properties of SPECT and PET radioligands, few studies have been capable of concurrently examining striatal and extrastriatal D~2/3~ binding in PD patients. The fact that most radioligands are best suited towards quantitation of binding in striatal or extrastriatal sites, but not both at the same time, makes a comprehensive understanding of the relative magnitude of PD-induced D~2/3~ BP~ND~ changes across areas compared to healthy subjects difficult to capture. \[^11^C\]raclopride is effective at measuring striatal (and to an extent thalamic) D~2/3~ levels but cannot provide reliable estimates in most extrastriatal areas, while \[^11^C\]FLB-457 can assess extrastriatal regions but is not able to quantify binding in the striatum (as it does not reach equilibrium in a reasonable timeframe) ([@bb0135]; [@bb0205]). The D~3~ preferring ligand \[^11^C\]-(+)-PHNO has infrequently been used to estimate dopamine receptor binding in PD ([@bb0045]; [@bb0330]), but cannot provide full characterization of limbic and cortical regions ([@bb0115]).

\[^18^F\]fallypride ((*S*)-N-\[(1 allyl-2-pyrrolidinyl)methyl\]-5-(3\[18F\]fluoropropyl)-2,3-dimethoxybenzamide) is a high-affinity D~2/3~ radioligand that can provide accurate estimates of binding in both striatal and extrastriatal regions, allowing for concurrent estimation of dopamine D~2/3~ receptor levels (i.e. nondisplaceable binding potential, BP~ND~) throughout the brain ([@bb0245]; [@bb0300]). Furthermore, \[^18^F\]fallypride has been successfully applied in a PD cohort ([@bb0095]). We examined regional \[^18^F\]fallypride binding in a large cohort of PD patients and age-matched healthy control (HC) subjects in order to simultaneously determine differences in striatal and extrastriatal D~2/3~ BP~ND~, with the goal of providing cortical and subcortical binding potentials that can be directly compared. As a secondary objective, we assessed if D~2/3~ BP~ND~ reflected motor severity in PD patients.

1.2. Methods {#s0010}
============

1.2.1. Participants {#s0015}
-------------------

PD participants were recruited from the Movement Disorders Clinic at Vanderbilt University Medical Center. All met UK Brain Bank criteria for a diagnosis of PD and were prescribed levodopa and DA agonist medications (including pramipexole, ropinirole, and rotigotine) for relief of motor symptoms. Daily doses of dopamine replacement therapy were converted to levodopa equivalent dose ([@bb0420]). Patients were excluded if they had an implanted deep brain stimulator, received antipsychotic treatments, suffered from comorbid neuropsychiatric, cerebrovascular, or cardiovascular disease, could not tolerate a brain MRI/PET study, or dopaminergic medication withdrawal. HC subjects ([@bb0085]; [@bb0080]) did not have a history of psychiatric illness, head trauma, substance abuse, diabetes, or medical condition that precluded MRI collection, nor could they use tobacco. No participants took psychostimulant or psychotropic medications (with an exception for occasional use of benzodiazepines as sleep medication) over the preceding 6 months, and did not consume excessive alcohol. Urine drug tests were administered to all participants to ensure the absence of amphetamine, barbiturates, cocaine, marijuana, or opiates.

A neurologic exam was performed on all participants, in order to exclude parkinsonism in HC subjects. PD patients completed part II of the Movement Disorders Society-United Parkinson\'s disease Rating Scale (MDS-UPDRS) (a self-reported assessment of the impact of PD on activities of daily living), and part III (an assessment of motor function in PD) in the Off-medication condition ([@bb0175]; [@bb0435]). Dopamine medications were withheld for \>40 h prior to PET imaging for DA agonists and \>16 h for levodopa prior to PET imaging (the half-life of levodopa, ropinirole, and pramipexole are approximately 1.5, 6, and 8--12 h respectively ([@bb0035]; [@bb0125]; [@bb0425]; [@bb0445]). Cognitive screening was performed using the Montreal Cognitive Assessment (MoCA) to rule out patients with frank dementia ([@bb0320]), requiring a score of at least 22. In PD patients, depression was screened using the Center for Epidemiologic Studies Depression Scale Revised (CESD-R) ([@bb0340]). The presence of medication-induced impulsive compulsive behaviors (ICBs) as a potential confounding factor was also assessed using a semi-structured interview with patient and partner.

Demographic and clinical features for PD patients (*n* = 35), as well as HC subjects (*n* = 31) are presented in [Table 1](#t0005){ref-type="table"}. Both groups had a similar average age and sex distribution. The side of symptom severity (both onset and based on motor testing) was more prominent in the left hemi-body of PD patients, who expressed moderate PD progression with an average disease duration of 5.9 ± 3.9 years. Of this cohort, 17 had symptoms of Impulsive Compulsive Behaviors.Table 1Demographic and clinical evaluation from the two participant groups.Table 1VariablesPDHC*p-*ValueN3531Sex (M/F)24/1121/100.94Age (years)61.8 ± 8.558.1 ± 11.30.17Disease duration (years)5.9 ± 3.9n/a--CES-D15.7 ± 8.7n/a--Laterality score (− = left worse, + = right worse)−2.45 ± 10.7n/a--Left worse/right worse (individual)22/13MDS-UPDRSPart II21.8 ± 7.7n/a--Part III (OFF)30.0 ± 11.1n/a--Dopamine replacement therapyTotal LEDD (mg/day)632.7 ± 418.7n/a--Agonist single dose equivalent (mg/day)103.9 ± 71.6n/a--[^1][^2][^3][^4][^5][^6][^7][^8]

Written informed consent was obtained from all subjects, and the study was performed in accordance with the Institutional Review Board at Vanderbilt University, adhering to the ethical standards stipulated by the Declaration of Helsinki and its amendments.

1.2.2. Magnetic resonance imaging {#s0020}
---------------------------------

MRI scans were completed prior to PET scans in order to provide high-resolution structural delineation. Both PD and HC subjects were scanned at 3.0T (Philips, Best, The Netherlands) using body coil transmission and 8-channel SENSE reception. All underwent a T~1~-weighted high-resolution anatomical scan (MPRAGE; spatial resolution = 1 × 1 × 1 mm^3^; TR/TE = 8.9/4.6 ms).

1.2.3. Fallypride PET data acquisition {#s0025}
--------------------------------------

\[^18^F\]fallypride was synthesized in the radiochemistry laboratory consistent with the synthesis and quality control procedures outlined by US Food and Drug Administration INDs 47,245 and 120,035. Data were collected on a GE Discovery STE PET/CT scanner. Serial scan acquisition began simultaneously with a 5.0 mCi slow bolus injection of \[^18^F\]fallypride (specific activity \>3000 Ci/mmol). CT scans were collected prior to each of the three emissions scans for the purpose of attenuation correction. Together, the scans lasted approximately 3.5 h with two breaks of 15--20 min (beginning approximately 70 min and 135 min after the beginning of the scan, respectively) included for patient comfort. During breaks, patients remained at rest but were permitted to stretch. Data for PD and HC subjects were acquired using identical MRI and PET technical parameters, with the single exception of a slightly different PET acquisition time protocol for the second and third dynamic runs, although total scan duration was similar (Supplementary Table 1; see [@bb0085]; [@bb0080]). In past PET studies, differences in acquisition time protocol were not found to be a significant confound ([@bb0065]; [@bb0400]).

1.2.4. Fallypride PET data processing {#s0030}
-------------------------------------

Following attenuation correction and decay correction, serial PET scans were co-registered using Statistical Parametric Mapping software (SPM8, Wellcome Trust Centre for Neuroimaging, London, UK, [http://www.fil.ion.ucl.ac.uk/spm/software/](http://www.fil.ion.ucl.ac.uk/spm/software){#ir0005}) to correct for motion across scanning periods with the last dynamic image of the first series serving as the reference image. The mean PET image produced by realignment was then co-registered to the subject\'s corresponding high-resolution T1 MRI image using FSL\'s FLIRT with 6 degrees of freedom (FSL v5.0.2.1, FMRIB, Oxford, UK).

D~2/3~ receptor levels were estimated using the simplified reference tissue model (SRTM) ([@bb0275]), performed in PMOD software (PMOD Technologies, Zurich Switzerland) to measure \[^18^F\]fallypride binding potential(BP~ND~; the ratio of specifically bound \[^18^F\]fallypride to its nondisplaceable concentration as defined under equilibrium conditions). Voxel-wise estimates were generated using a published basis function fitting approach ([@bb0190]) conducted in the PXMOD module of PMOD. The rate constants were specified as k~2a~ minimum = 0.006 min^−1^ and k~2a~ maximum = 0.6 min^−1^. Due to the very limited expression of D~2/3~ receptors in the cerebellum ([@bb0070]), it was selected as the reference region ([@bb0245]; [@bb0250]). Subject-space analyses were conducted by warping baseline BP~ND~ images to T1 space with the saved FSL FLIRT transform matrices. For voxel-wise analyses, subject-space BP~ND~ images were registered to Montreal Neurological Institute (MNI) space using FSL\'s FNIRT (FSL v5.0.2.1, FMRIB, Oxford, UK).

Voxel-wise analysis was first applied to assess putative subcortical and cortical differences between groups, with specific attention towards potential sub-regional distinctions in the broader mesiotemporal and prefrontal cortices. Next, subcortical regions of interest (ROIs), including the caudate (head), putamen (whole body), globus pallidus, ventral striatum, amygdala, hippocampus, ventral midbrain, thalamus, and cerebellum, were manually segmented on the T~1~-weighted MRI scans by a neuroradiologist (RMK) and neurologist (DOC) experienced in PET and MRI data analysis, and transferred to the co-registered PET studies through the FLIRT FSL transformation matrix. Manual segmentation methods followed established anatomical criteria, capturing the central portion of the selected region to gather the most representative sample. This method was selected in order to best avoid partial volume effects in densely arranged subcortical nuclei, and were applied so as to avoid the potential confound of inter-subject structural variability ([@bb0255]). The caudate, putamen, and globus pallidus were manually drawn on axial slices approximately 2--12 mm above the ACPC line. The ventral striatum was segmented on coronal slices with the criteria of [@bb0290]. The amygdala can be identified on axial slices 6--20 mm below the ACPC line, 12--28 mm lateral to the midline, and 2--12 mm behind the plane of the anterior commissure ([@bb0380]). To minimize partial voluming of the striatum, amygdala ROIs were defined 10--16 mm beneath the ACPC plane. The ventral midbrain was drawn on axial slices in 9--14 mm below the ACPC line, and the thalamus was segmented 2--12 mm above the ACPC line ([@bb0380]). The cerebellar ROI was drawn centrally within the structure to avoid partial voluming of ventral midbrain or cortical signal, and contained an approximately equal distribution of grey and white matter. Due to difficulty capturing the extent of the hippocampus using manual methods, it was defined using a previously published automatic subject space segmentation method ([@bb0015]). All ROIs were defined bilaterally. In order to account for potentially divergent structure size between groups, ROI volumes were collected and preserved for statistical analysis.

1.2.5. Hypothesis testing and statistical analysis {#s0035}
--------------------------------------------------

Group differences in demographic and clinical parameters, as well as ROI volume, were evaluated using Mann Whitney *U* tests. Sex differences were evaluated with a chi-square test. A voxel-wise analysis investigated PD-related group differences in D~2/3~ BP~ND~ across cortical and subcortical regions. Age and sex were included as covariates, due to previous evidence that these factors influence D~2/3~ receptor status ([@bb0300]; [@bb0335]), and significance criteria consisted of an uncorrected *p* \< 0.005. Multiple comparisons correction was accomplished by controlling cluster-level FDR at 0.05. This analysis was completed using SPM8. In a secondary, exploratory voxel-wise analysis utilizing identical statistical parameters, BP~ND~ maps for subjects expressing more severe PD symptoms on the right side of the body were flipped across the rostral-caudal axis of the axial plane. This step was completed in order to ensure that the more degenerated side of the dopaminergic system (contralateral to more severe motor deficits) was aligned for all subjects ([@bb0010]).

To test the hypothesis that PD patients have different dopamine D~2/3~ receptor expression in specific striatal and subcortical extrastriatal areas, mean group regional \[^18^F\]fallypride BP~ND~ was analyzed via a general linear regression model (GLM), where within-ROI BP~ND~ was the dependent variable and PD status was the primary independent variable. Age and sex were included as covariates. ROI volume was also specified as a covariate, to ensure that any differences were not due to overall structural atrophy. False discovery rate (FDR) was controlled at 0.1 to correct for multiple comparisons, in concordance with the threshold recommended in the first description of the method ([@bb0030]). All analyses were performed using SPSS Statistics 24 (IBM, Armonk, NY, USA) and R (R Foundation for Statistical Computing, Vienna, 2016). In addition to the ROI analysis, we performed a post-hoc evaluation to quantify the magnitude of BP~ND~ differences in regions where voxel-wise distinctions were present, but were not captured by the hand-drawn ROI analysis. Mean group BP~ND~ values were extracted from standard space (MNI) in areas where voxel-wise clusters were manifested using the Automated Anatomical Labeling (AAL) atlas or manual segmentation methods. This served as a post-hoc method of evaluating the extent of regional differences identified by the voxel-wise analysis.

The relationship between regional \[^18^F\]fallypride BP~ND~ and PD severity was also examined using a partial Pearson\'s correlation covarying for age, sex, ROI volume, disease duration, and levodopa equivalent daily dose (LEDD). This process was repeated for both MDS-UPDRS Part II (a measure of activities of daily living) and MDS-UPDRS Part III-Off (a measure of motor symptom severity), and the results were controlled at FDR of 0.1 to correct for multiple comparisons. A secondary voxel-wise analysis was also completed for MDS-UPDRS Parts II and III using SPM8, specifying age, sex, disease duration, and LEDD as covariates, an uncorrected threshold of *p* \< 0.005, and cluster-level FDR controlled at 0.05. This voxel-wise analysis was also repeated using images flipped across the y-axis of the axial plane to align the side of the brain contralateral to the side of greater PD motor symptom severity in all subjects.

1.3. Results {#s0040}
============

1.3.1. Voxel-wise fallypride binding potential differences {#s0045}
----------------------------------------------------------

Using the voxel-wise method covarying for age and sex, significant reductions of \[^18^F\]fallypride BP~ND~ in PD patients localized to subcortical clusters in the amygdala and hippocampus, ventral midbrain, LC, caudate nucleus, and globus pallidus. Cortical differences localized to the anterior and medial temporal cortical regions (temporal pole, parahippocampal, and entorhinal cortices). In no region was D~2/3~ BP~ND~ increased in patients with PD compared to HC participants. [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"} display a map of significant clusters overlaid on a standard-space brain, in an array of coronal and axial slices respectively. A similar cluster pattern was evident when images were aligned so that the right side of the brain was contralateral to the side of greater PD motor symptom severity in all subjects; although largely symmetrical, cluster size was slightly more extensive in the right-sided midbrain and left-sided temporal cortex (Supplementary Figs. 3 & 4).Fig. 1Voxel-wise \[^18^F\]fallypride binding potential analysis. Map of significant clusters where \[^18^F\]-fallypride BP~ND~ was reduced in PD, overlaid on coronal slices of an MNI template brain. All survived cluster-level FDR correction at *p* \< 0.05, and localize to areas including (A) the striatum, globus pallidus, and temporal cortex, (B) the amygdala and hippocampus, (C) the ventral midbrain and thalamus, and (D) the locus coeruleus.Fig. 1Fig. 2Voxel-wise \[^18^F\]fallypride binding potential analysis. Map of significant clusters where \[^18^F\]-fallypride BP~ND~ was reduced in PD, overlaid on axial slices of an MNI template brain. All survived cluster-level FDR correction at *p* \< 0.05, and localize to areas including (A) the temporal cortex, (B) the amygdala, hippocampus, ventral midbrain, and locus coeruleus, and (C) the thalamus, striatum, and globus pallidus.Fig. 2

1.3.2. Quantitative \[^18^F\]fallypride BP~ND~ differences in PD {#s0050}
----------------------------------------------------------------

To quantitate group differences in mean subcortical regional \[^18^F\]fallypride BP~ND~ we applied a GLM analytic approach, including group as an independent variable, and age, sex, and volume as covariates. In order of the magnitude of percent difference, significant BP~ND~ reductions in PD patients were evident in the ventral midbrain (*p* \< 0.001; 39% decrease), amygdala (*p* \< 0.001; 33% decrease), thalamus (*p* \< 0.001; 30% decrease), hippocampus (*p* \< 0.001; 22% decrease), globus pallidus (*p* = 0.002; 16% decrease), and caudate (*p* = 0.005; 11% decrease). No significant differences were evident in the putamen (*p* = 0.56; 2% difference), or ventral striatum (*p* = 0.66; 2% difference). (See Supplementary Table 3 for full description of mean regional binding potentials). [Fig. 3](#f0015){ref-type="fig"} presents the individual and group mean regional BP~ND~ values for the ROIs, alongside segmentation visualization.Fig. 3Mean regional \[^18^F\]fallypride binding potential analysis. (A--O) Representative coronal and axial slices for a single subject show an example of the manual segmentation routine for eight different subcortical structures, including (A) caudate, (C) putamen, (E) globus pallidus, (G) ventral striatum, (I) amygdala, (K) hippocampus, (M) thalamus, and (O) midbrain. (B--P) Bar graphs of the mean \[^18^F\]fallypride BP~ND~ in each corresponding region, with error bars representing the standard deviation of the mean, and scatterplots representing individual regional means. There were significant differences in mean regional BP~ND~ between the PD and HC group in the caudate (A--B), globus pallidus (E--F), amygdala (I--J), hippocampus (K--L), thalamus (M--N), and midbrain (O--P). No group differences were observed in the putamen (C--D) or ventral striatum (G--H).Fig. 3

To quantify the extent of BP~ND~ differences in regions where voxel-wise distinctions were present, but that were not captured by the hand-drawn ROI analysis, we applied the AAL atlas to define the bilateral combined entorhinal and parahippocampal cortices, the inferior and middle temporal gyri, and the temporal pole. The locus coeruleus (LC) was defined by uniting six contiguous 2 mm boxes bilaterally, centered in standard space (MNI) according to the mean values on the *x* and *y* axis as discussed by [@bb0215] and [@bb0240]. This approach revealed PD-induced BP~ND~ decreases of a similar magnitude to those observed in other extrastriatal areas: LC (27% decrease), entorhinal and parahippocampal cortices (19% decrease), inferior (25% decrease) and middle (23% decrease) temporal gyri, and temporal pole (24% decrease). (See Supplementary Table 5 for full description of mean regional binding potentials, and Supplementary Figs. 1 and 2 for depiction of the segmentation protocol as well as group and individual regional means).

1.3.3. Relationships between fallypride binding potential and PD motor severity {#s0055}
-------------------------------------------------------------------------------

The relationship of BP~ND~ to MDS-UPDRS Parts II and III-Off scores was assessed using a voxel-wise analysis while covarying for age. We observed a positive relationship between \[^18^F\]fallypride BP~ND~ and UPDRS Part III-Off in a right hemisphere cluster localized to the globus pallidus and anterior putamen, and a left hemisphere cluster localized to the posterior putamen. No significant clusters were observed when BP~ND~ was tested for association with UPDRS Part II scores. Supplemental Fig. 4 displays a map of significant clusters overlaid on a standard-space map. When images were aligned so that the right side of the brain was contralateral to the side of increased PD motor symptom severity in all subjects, a significant cluster was evident only in the left-sided putamen and globus pallidus (Supplementary Fig. 6).

1.3.4. Regional relationships between fallypride binding potential and PD severity {#s0060}
----------------------------------------------------------------------------------

To further evaluate the association between D~2/3~ BP~ND~ and motor severity, we assessed the relationship between \[^18^F\]fallypride BP~ND~ and UPDRS Part III-Off scores in the hand-defined bilateral putamen and globus pallidus, while covarying for factors that may influence motor severity. This included age, sex, ROI volume, disease duration, and LEDD. We observed a significant positive correlation between BP~ND~ and scores on the MDS-UPDRS Part III in the putamen (*r* = 0.488, *p* = 0.006) and globus pallidus (*r* = 0.449, *p* = 0.013). No significant association was present between MDS-UPDRS Part III and BP~ND~ in any other ROI. Again, we did not see a significant relationship between \[^18^F\]fallypride BP~ND~ and MDS-UPDRS Part II. [Fig. 4](#f0020){ref-type="fig"} displays the graphs of MDS-UPDRS Part III score with BP~ND~ in the putamen and globus pallidus.Fig. 4MDS-UPDRS Part III vs. \[^18^F\]-fallypride binding potential. Scatterplots of BP~ND~ (y-axis) vs. scores on the MDS-UPDRS Part III off-medication (x-axis) fit with a linear regression for the PD group. Age, sex, ROI volume, disease duration, and LEDD were included as covariates in this analysis. A significant positive correlation between BP~ND~ and MDS-UPDRS Part III score was observed for the (A) putamen and (B) globus pallidus. No significant correlations were observed between BP~ND~ and MDS-UPDRS Part II for any ROI. This indicates that there is a positive relationship between D~2/3~ expression in the putamen and globus pallidus, and severity of PD motor symptoms.Fig. 4

1.4. Discussion {#s0065}
===============

We observed widespread reductions in D~2/3~ receptor binding in PD patients, indicating changes to D~2/3~ receptor availability in regions that relate to both the motor and nonmotor aspects of PD. The sites in which D~2/3~ BP~ND~ decreases were observed include basal ganglia, limbic, thalamic, and cortical regions, as well as the LC. Our discussion focuses on these D~2/3~ BP~ND~ group differences in the basal ganglia (and relationships with the severity of off-motor symptoms in PD), norepinephrine-related extrastriatal areas, and limbic and thalamocortical regions. Broadly, the pattern of BP~ND~ reduction in the basal ganglia is of a lower magnitude, indicative of a complex relationship between presynaptic receptor loss and postsynaptic receptor upregulation, while extrastriatal areas show larger differences between the PD and HC groups.

1.4.1. Technical considerations {#s0070}
-------------------------------

The interpretation of data presented in this report requires the consideration of several technical parameters relevant to determining the neurobiological origin of PD-related changes reflected in \[^18^F\]fallypride BP~ND~ values. D~2/3~ receptors are expressed on dopaminergic neurons, where they can operate presynaptically as autoreceptors ([@bb0260]; [@bb0295]), or as postsynaptic receptors present on striatal medium spiny neurons and cortical pyramidal cells ([@bb0005]; [@bb0155]). Thus, a decrease in \[^18^F\]fallypride BP~ND~ values could potentially convey a loss of autoreceptors secondary to degeneration of mesotelencephalic dopaminergic neurons, or a decrease in postsynaptic D~2/3~ expression. However, the latter possibility appears unlikely to be a primary source of decline in receptor availability, as nigrostriatal dopaminergic denervation elicits a compensatory upregulation of postsynaptic receptors early in the course of PD ([@bb0130]). Considering that our subjects were relatively early in the course of motor parkinsonism, it is likely that the present report of decreased \[^18^F\]fallypride BP~ND~ is a measure of presynaptic D~2/3~ autoreceptor density, influenced by ongoing degeneration of dopaminergic neurons. Finally, interpretation of \[^18^F\]fallypride BP~ND~ must also account for the combined influence of long-term receptor expression and the level of dopamine in the synaptic cleft which competes with \[^18^F\]fallypride binding leading to an underestimation of the long-term D~2/3~ expression level.

1.4.2. Nigrostriatal and pallidal D2/3 expression: dopaminergic denervation and motor severity {#s0075}
----------------------------------------------------------------------------------------------

Reduced D~2/3~ levels were observed in the ventral midbrain, caudate nucleus, and globus pallidus of PD patients. The initial and greatest loss of midbrain dopaminergic neurons in PD occurs in the ventrolateral substantia nigra ([@bb0165]). It is therefore likely that the ventral midbrain reduction in BP~ND~ reflects nigral dopaminergic cell loss ([@bb0165]), and the consequent loss of somatodendritic D~2/3~ autoreceptors. In contrast, D~2/3~ BP~ND~ did not differ in the putamen and ventral striatum between PD and HC subjects. While the loss of presynaptic terminal autoreceptors due to dopaminergic cell death likely accounts for the decrease in BP~ND~ observed in several regions (caudate and globus pallidus), D~2/3~ BP~ND~ is unchanged in certain other areas (putamen and ventral striatum), although these regions also suffer dopaminergic denervation. This is particularly striking in the putamen where dopaminergic denervation is typically greatest. The lack of significant differences between subjects with PD and control subjects presumably reflects a combination of postsynaptic receptor upregulation ([@bb0130]), combined with a decrease in terminal autoreceptors and extracellular DA levels. Post-synaptically, long-term binding decrements over the course of PD likely involve the loss of D~2/3~ expressing dendritic spines ([@bb0405]; [@bb0450]) a concept further emphasized by past evidence of putaminal atrophy ([@bb0410]). In our hands, the combined influence of these factors on D~2/3~ in the putamen sums to no significant change. This may explain equivalent putaminal BP~ND~ results between patients and controls, but divergent values in the caudate. Because ventral midbrain dopaminergic cell death occurs in the ventrolateral substantia nigra (containing cell bodies from which the dopaminergic projection to the more dorsolateral and posterior putamen emanates), the greatest DA reductions more heavily affect the putamen than the caudate; these losses likely exceed a critical threshold and produce notable receptor upregulation in the region ([@bb0165]; [@bb0200]; [@bb0350]; [@bb0355]). By contrast, either this threshold is not reached in other brain regions, or those areas lack the same compensatory upregulation that occurs in the putamen.

In addition to differences in long-term receptor expression, the lack of an observed BP~ND~ difference in the putamen could also be affected by acute reductions in synaptic dopamine, which may contribute to the positive correlation between motor symptoms and D~2/3~ binding in the region, which is likely weighted on the former factor. Patients with more severe motor symptoms after standardized dopamine withdrawal presumably have less endogenous synaptic dopamine levels after medication washout, resulting in less competition with \[^18^F\]fallypride binding. This concept could be further emphasized by the finding that this positive association was present only on the left hemisphere of the brain, following alignment of all BP~ND~ images so that more severe motor symptoms were expressed in the right hemi-body. The fact that the correlation is present on the side of the dopaminergic system less affected by denervation, where DA levels are likely more dynamic and sensitive to the presence of medication, could strengthen the association between observed striatal BP~ND~ and synaptic DA. Future studies employing pharmacological methods of manipulating dopamine levels may clarify this relationship between endogenous dopamine, regional differences in D~2/3~ receptor binding, and motor severity.

Our findings of D~2/3~ reductions in the globus pallidus are similar to previous observations in a \[^11^C\]-(+)-PHNO study of PD reporting significantly reduced binding in comparison to control subjects ([@bb0045]). However, this is the first study to indicate a relationship between motor symptoms and pallidal D~2/3~ expression after medication washout. This association is in agreement with a recent study linking external globus pallidus function to motor severity in dopaminergic denervation mouse models ([@bb0285]).

1.4.3. D~2/3~ receptor expression in regions receiving dense noradrenergic innervation {#s0080}
--------------------------------------------------------------------------------------

We also found D~2/3~ BP~ND~ changes in a number of regions that are classically known as noradrenergic sites, and receive less dense dopaminergic inputs. In PD patients, D~2/3~ BP~ND~ was decreased in the LC, a structure containing a large population of noradrenergic neurons that provide most norepinephrine in the forebrain. This effect was also present in the hippocampus, as well as several cortical sites in which norepinephrine concentrations are greater than those of dopamine (entorhinal/parahippocampal cortices, and temporal pole). While nigrostriatal denervation bears a clear link with the motor symptoms of PD, the association between the progressive loss of the noradrenergic system and many non-motor features has been amply described ([@bb0075]). The degeneration of noradrenergic LC neurons in PD has long been known ([@bb0160]) and more recently the presence of α-synuclein inclusions in the LC has been reported ([@bb0060]). Moreover, noradrenergic loss in several cortical areas, including the prefrontal cortex, is comparable to or greater than the corresponding decrease in dopamine content in these structures in MPTP-induced parkinsonism ([@bb0120]) and in idiopathic PD ([@bb0375]). D~2~ receptors are expressed on LC neurons ([@bb0280]), suggesting that the degeneration of LC neurons may underlie the decrease in BP~ND~ due to postsynaptic D~2/3~ loss in subjects with PD. However, dopamine also positively regulates LC noradrenergic activity via reciprocal projections between ventral midbrain dopaminergic neurons and the LC ([@bb0090]; [@bb0185]). As such, the loss of presynaptic D~2/3~ expressed on dopaminergic midbrain projections to the LC may also contribute to the decrease in D~2/3~ binding in the region.

In the hippocampus, the density of dopaminergic innervation from the midbrain is sparse ([@bb0325]), meaning that decreased BP~ND~ there is less likely due to presynaptic D~2/3~. Recent evidence has indicated that noradrenergic projections to the hippocampus and associated cortical regions may account for a large proportion of dopamine release in these structures ([@bb0100]; [@bb0395]). Combined with the finding that norepinephrine may act as a D~2/3~ receptor agonist ([@bb0365]), the D~2/3~ BP~ND~ reductions in the LC, hippocampus, and medial temporal cortex could instead indicate widespread dysfunction of the noradrenergic system and its terminal fields, a well-described. Degeneration of this system, centering on the LC, is suggested as a major contributor to cognitive and other behavioral non-motor symptoms of PD ([@bb0025]; [@bb0360]; [@bb0440]).

1.4.4. Limbic and thalamocortical D2/3 expression in PD {#s0085}
-------------------------------------------------------

The dopaminergic innervation of the amygdala arises from ventral midbrain neurons largely targeting the basolateral complex ([@bb0140]), where D~2/3~ receptors regulate reward learning processes ([@bb0040]; [@bb0105]). The amygdala is known to be vulnerable to PD pathology, given the presence of Lewy body inclusions and susceptibility to atrophy ([@bb0055]; [@bb0225]). This pattern of degeneration is linked to the manifestation of depression in PD, where symptom severity correlates with reduced amygdalar volume ([@bb0430]), and apparent hypofunction ([@bb0110]; [@bb0390]). Deficits in emotional processing constitute another non-motor symptom commonly attributed to dopaminergic innervation of the amygdala ([@bb0050]), supported by the apparent influence of DA medication state on both behavioral and amygdalar hemodynamic response to emotional stimuli ([@bb0415]). D~2/3~ agonist medications show efficacy in ameliorating depression in PD ([@bb0020]), an effect that could potentially be induced by targeting D~2/3~ in the amygdala, where D~2/3~ agonists significantly displace receptor-bound \[^11^C\]FLB-457 ([@bb0220]). Therefore, altered D~2/3~ BP~ND~ in the amygdala may account for some of the non-motor symptoms related to PD-depression. The extent of D~2/3~ receptor reductions to this region in our cohort of non-depressed patients suggests that this is an early area of vulnerability in PD which may contribute to subsequent depression risk.

The thalamus expresses notable D~2/3~ populations in the midline intralaminar and mediodorsal nuclei ([@bb0145]; [@bb0345]). Due to the selection of an ROI in the middle of the superior-inferior thalamic axis, BP~ND~ in this ROI is heavily weighted towards D~2/3~ expression in the medial thalamus. Although the function of thalamic D~2/3~ receptors is largely unexplored, the role of altered thalamocortical networks in the manifestation of motor symptoms of PD is well established ([@bb0370]). Anatomically, D~2/3~ populations in the thalamus integrate information from mesocortical and limbic regions and project to frontal cortical areas ([@bb0180]). Previous \[^11^C\]FLB-457 PET studies that show reductions in thalamic D~2/3~ binding also restrict these regional reductions to advanced, but not early, PD populations ([@bb0235]; [@bb0230]; [@bb0270]). In contrast, however, the degeneration of neurons in the centromedian-parafascicular complex occurs in both Hoehn and Yahr stage I/II and stage III/IV ([@bb0210]), suggesting that the loss of \[^11^C\]FLB-457 binding may preferentially reflect the loss of certain afferents to these intralaminar nuclei. In a similar manner to regions already described, losses of presynaptic autoreceptors could also play a role.

We do not observe differences in frontal cortical areas. Previous \[^11^C\]FLB-457 studies have indicated reductions that localize to these regions ([@bb0235]; [@bb0230]; [@bb0270]); however, previous preclinical experiments utilizing MPTP models have not always proved consistent with this evidence ([@bb0170]). Our result could be a product of the pharmacodynamic distinctions between \[^11^C\]FLB-457 and \[^18^F\]fallypride ([@bb0315]). However, this also may be due to our cohort of moderately affected patients, in whom previously described frontal cortical D~2/3~ reductions are not manifest until later in the course of the illness. We did, however, uncover differences in D~2/3~ receptors in the perirhinal and parahippocampal areas. These regions are critically involved in memory and learning processes ([@bb0455]), which are often impaired in PD patients ([@bb0305]). Future investigations on the clinical relevance of these findings may improve the characterization of cognitive changes early in PD.

1.5. Conclusions {#s0090}
================

Although a decided advantage of our investigation was the number of patients with PD recruited to the study, our PD cohort included a larger proportion (\~50%) of individuals with compulsive reward-based behaviors than would be expected in a typical PD population ([@bb0150]). We noted differences between PD patients with and without compulsive behaviors only in the ventral striatum and putamen, which were not significantly different between the HC and overall PD group; the lack of significant differences in these areas were preserved even when the subgroups were compared with the HC group separately (see Supplementary Table 7). Thus, we believe this is not a significant limitation to the interpretation of changes in PD. Also, the generalizability of the sample is affected by the relatively specific subject selection criteria, including patients with mild to moderate PD, who could tolerate an extensive dopamine washout, and were without depression, dementia, or psychosis.

In light of the close proximity of basal ganglia structures, there is potential for partial volume errors. We especially considered this given the significant association between D~2/3~ BP~ND~ and UPDRS Part III in the putamen and globus pallidus, two adjacent structures. However, the presence of a mean D~2/3~ BP~ND~ difference between groups in the globus pallidus but not in the putamen, in addition to the broad localization of the cluster observed in the voxel-wise correlation analysis, gives us confidence that our results in both regions are largely distinct. Additionally, all native subject space analyses included ROI volume as a covariate, which likely decreases the confounding effect of divergent patterns of atrophy in adjacent areas.

As a cross-sectional study, the present work can only tentatively point to possible changes in D~2/3~ BP~ND~ changes that occur over the course of disease progression. Additionally, the use of D~2/3~ agonists by all those enrolled makes it difficult to disentangle the effects of chronic long-term medication exposure from those purely induced by PD. Although past studies have assessed changes to extrastriatal D~2/3~ binding and dopaminergic biomarkers over time ([@bb0235]; [@bb0310]), future studies should longitudinally assess extrastriatal D~2/3~ expression in a de novo PD population. Relating non-motor symptoms (e.g. mood and cognitive impairment), to receptor-level changes in these regions will be necessary to define a causal relationship to non-motor symptoms in PD. Overall, our findings emphasize that PD is associated with widespread changes in the expression of D~2/3~ receptors, and point to increased scrutiny of the contribution of noradrenergic alterations as contributing to changes in dopaminergic systems in PD. These changes appear to affect regions implicated in the development of both motor and nonmotor features of the disease, where D~2/3~ losses proceed differently in the basal ganglia and extrastriatal areas.
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Appendix A. Supplementary data {#s0100}
==============================

The supplementary data section provides 1.) PET acquisition parameters; 2.) a full description of mean ROI volume and BPnd values; 3.) a measure of effect size for all ROI-based analyses; 4.) standard-space ROI visualization and standard-space ROI BPnd scatterplots; 5.) visualization of supplementary whole-brain voxel-wise analysis considering PD symptom laterality; 6.) visualization of supplementary whole-brain voxel-wise analysis evaluating correlation between BPnd and UPDRS Part III.Image 1

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.nicl.2018.02.010>.

[^1]: Data are shown as mean ± standard deviation.

[^2]: MDS-UPDRS Part III conducted off medication (36 h for DAgonist and 16 for LDOPA).

[^3]: PD: Parkinson\'s Disease.

[^4]: AMNART: American version of the National Adult Reading Test.

[^5]: CES-D: Center for Epidemiologic Studies Depression Scale.

[^6]: MDS-UPDRS: Movement Disorders Society-United Parkinsons Disease Rating Scale.

[^7]: BIS: Barratt Impulsivity Scale.

[^8]: LEDD: Levodopa Daily Dose.
